For some women with breast cancer, taking tamoxifen for 10 years after primary treatment (adjuvant therapy) leads to a greater reduction in breast cancer recurrences and deaths than taking the drug for only 5 years, according to the results of a large international clinical trial.
The findings from the ATLAS trial—presented at the San Antonio Breast Cancer Symposium (SABCS) and published in The Lancet on December 5—are likely to change clinical practice, several researchers said. Read more >>
A MESSAGE TO READERS
NCI Cancer Bulletin Publication Break
The NCI Cancer Bulletin will not be published on December 25. Our next issue will be published on January 8, when we resume our usual biweekly publication schedule.
- Abiraterone Approval Extended to Treat Late-Stage Prostate Cancer
- Cabozantinib Approved to Treat Rare Type of Thyroid Cancer
- New National Cancer Advisory Board Members Named
- NCI Recognizes 12 Clinical Investigators with Leadership Awards
- National Cancer Advisory Board Discusses NCI Funding Patterns, Program Updates
- NCI FY2013 Budget Proposal Published Online
- NCI E-Books Available on Mobile Website
- Annual Report on NCI Disparities Research Released
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at email@example.com.